The Lancet最新文献

筛选
英文 中文
Priorities for sickle cell disease global research and implementation. 镰状细胞病全球研究和实施的优先事项。
IF 98.4 1区 医学
The Lancet Pub Date : 2024-11-09 Epub Date: 2024-07-10 DOI: 10.1016/S0140-6736(24)01400-4
Ambroise Wonkam, Nchangwi Syntia Munung, Aldiouma Guindo, Obiageli Nnodu
{"title":"Priorities for sickle cell disease global research and implementation.","authors":"Ambroise Wonkam, Nchangwi Syntia Munung, Aldiouma Guindo, Obiageli Nnodu","doi":"10.1016/S0140-6736(24)01400-4","DOIUrl":"10.1016/S0140-6736(24)01400-4","url":null,"abstract":"","PeriodicalId":18014,"journal":{"name":"The Lancet","volume":null,"pages":null},"PeriodicalIF":98.4,"publicationDate":"2024-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141603820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Addressing global gun violence: a Lancet Commission on Global Gun Violence and Health. 应对全球枪支暴力:柳叶刀全球枪支暴力与健康委员会。
IF 98.4 1区 医学
The Lancet Pub Date : 2024-11-09 Epub Date: 2024-09-03 DOI: 10.1016/S0140-6736(24)01697-0
Adnan A Hyder, Lorena Barberia
{"title":"Addressing global gun violence: a Lancet Commission on Global Gun Violence and Health.","authors":"Adnan A Hyder, Lorena Barberia","doi":"10.1016/S0140-6736(24)01697-0","DOIUrl":"10.1016/S0140-6736(24)01697-0","url":null,"abstract":"","PeriodicalId":18014,"journal":{"name":"The Lancet","volume":null,"pages":null},"PeriodicalIF":98.4,"publicationDate":"2024-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142145920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Changing the culture of blood culture. 改变血液文化。
IF 98.4 1区 医学
The Lancet Pub Date : 2024-10-19 Epub Date: 2024-09-20 DOI: 10.1016/S0140-6736(24)01942-1
Sally Davies, Richard A Marfuggi, Rick A Bright, Steve Brozak, Michael Osterholm
{"title":"Changing the culture of blood culture.","authors":"Sally Davies, Richard A Marfuggi, Rick A Bright, Steve Brozak, Michael Osterholm","doi":"10.1016/S0140-6736(24)01942-1","DOIUrl":"10.1016/S0140-6736(24)01942-1","url":null,"abstract":"","PeriodicalId":18014,"journal":{"name":"The Lancet","volume":null,"pages":null},"PeriodicalIF":98.4,"publicationDate":"2024-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142308060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
More mpox data are needed to better respond to the public health emergency of international concern. 需要更多的 mpox 数据,以更好地应对这一国际关注的公共卫生紧急事件。
IF 98.4 1区 医学
The Lancet Pub Date : 2024-10-12 Epub Date: 2024-09-26 DOI: 10.1016/S0140-6736(24)02070-1
Liang Wang, George F Gao
{"title":"More mpox data are needed to better respond to the public health emergency of international concern.","authors":"Liang Wang, George F Gao","doi":"10.1016/S0140-6736(24)02070-1","DOIUrl":"10.1016/S0140-6736(24)02070-1","url":null,"abstract":"","PeriodicalId":18014,"journal":{"name":"The Lancet","volume":null,"pages":null},"PeriodicalIF":98.4,"publicationDate":"2024-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142349390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antimicrobial resistance: now is the time to revisit global commitments. 抗菌药耐药性:现在是重新审视全球承诺的时候了。
IF 98.4 1区 医学
The Lancet Pub Date : 2024-10-12 Epub Date: 2024-09-27 DOI: 10.1016/S0140-6736(24)02140-8
Jakob Forssmed
{"title":"Antimicrobial resistance: now is the time to revisit global commitments.","authors":"Jakob Forssmed","doi":"10.1016/S0140-6736(24)02140-8","DOIUrl":"10.1016/S0140-6736(24)02140-8","url":null,"abstract":"","PeriodicalId":18014,"journal":{"name":"The Lancet","volume":null,"pages":null},"PeriodicalIF":98.4,"publicationDate":"2024-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142349388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Health and humanitarian toll of Sudan's forgotten war. 苏丹被遗忘的战争造成的健康和人道主义损失。
IF 98.4 1区 医学
The Lancet Pub Date : 2024-10-12 Epub Date: 2024-09-24 DOI: 10.1016/S0140-6736(24)01939-1
Ezzeldin Saleh, Khalid M Dousa, Ahmed Babiker, Nour Elhouda At Alla Rahma, Hamad Abdel Hadi, Mustafa Elsayed, Suleima Ishag Elkhalifa, Sami Mahmoud Abdelkhair Momin, Ahmed Abubaker, Omer Mergani Nemery, Luai Mohmmed Bashir, Shahinaz Bedri, Nada Fadul, Yasir Hamad, Zahir Osman Eltahir Babiker
{"title":"Health and humanitarian toll of Sudan's forgotten war.","authors":"Ezzeldin Saleh, Khalid M Dousa, Ahmed Babiker, Nour Elhouda At Alla Rahma, Hamad Abdel Hadi, Mustafa Elsayed, Suleima Ishag Elkhalifa, Sami Mahmoud Abdelkhair Momin, Ahmed Abubaker, Omer Mergani Nemery, Luai Mohmmed Bashir, Shahinaz Bedri, Nada Fadul, Yasir Hamad, Zahir Osman Eltahir Babiker","doi":"10.1016/S0140-6736(24)01939-1","DOIUrl":"10.1016/S0140-6736(24)01939-1","url":null,"abstract":"","PeriodicalId":18014,"journal":{"name":"The Lancet","volume":null,"pages":null},"PeriodicalIF":98.4,"publicationDate":"2024-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142349389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The time to address the antibiotic pipeline and access crisis is now. 现在是解决抗生素管道和获取危机的时候了。
IF 98.4 1区 医学
The Lancet Pub Date : 2024-10-12 Epub Date: 2024-09-20 DOI: 10.1016/S0140-6736(24)01940-8
Manica Balasegaram, Kevin Outterson, John-Arne Røttingen
{"title":"The time to address the antibiotic pipeline and access crisis is now.","authors":"Manica Balasegaram, Kevin Outterson, John-Arne Røttingen","doi":"10.1016/S0140-6736(24)01940-8","DOIUrl":"10.1016/S0140-6736(24)01940-8","url":null,"abstract":"","PeriodicalId":18014,"journal":{"name":"The Lancet","volume":null,"pages":null},"PeriodicalIF":98.4,"publicationDate":"2024-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142308062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rechallenging with anti-PD-1 therapy in advanced renal cell carcinoma. 晚期肾细胞癌患者再次接受抗 PD-1 治疗。
IF 98.4 1区 医学
Lancet Pub Date : 2024-10-05 Epub Date: 2024-09-13 DOI: 10.1016/S0140-6736(24)01866-X
Zachary A Yochum, David A Braun
{"title":"Rechallenging with anti-PD-1 therapy in advanced renal cell carcinoma.","authors":"Zachary A Yochum, David A Braun","doi":"10.1016/S0140-6736(24)01866-X","DOIUrl":"10.1016/S0140-6736(24)01866-X","url":null,"abstract":"","PeriodicalId":18014,"journal":{"name":"Lancet","volume":null,"pages":null},"PeriodicalIF":98.4,"publicationDate":"2024-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142290383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reflections on The Lancet menopause Series. 对《柳叶刀》更年期系列的思考。
IF 98.4 1区 医学
Lancet Pub Date : 2024-10-05 Epub Date: 2024-09-25 DOI: 10.1016/S0140-6736(24)01710-0
Gemma Sharp, Alisha Randhawa, Anne Nileshni Fernando
{"title":"Reflections on The Lancet menopause Series.","authors":"Gemma Sharp, Alisha Randhawa, Anne Nileshni Fernando","doi":"10.1016/S0140-6736(24)01710-0","DOIUrl":"10.1016/S0140-6736(24)01710-0","url":null,"abstract":"","PeriodicalId":18014,"journal":{"name":"Lancet","volume":null,"pages":null},"PeriodicalIF":98.4,"publicationDate":"2024-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142349393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study. 对使用免疫检查点抑制剂的肾细胞癌患者进行替沃扎尼加尼沃单抗治疗与替沃扎尼单药治疗的比较:TiNivo-2 3 期研究结果。
IF 98.4 1区 医学
Lancet Pub Date : 2024-10-05 Epub Date: 2024-09-13 DOI: 10.1016/S0140-6736(24)01758-6
Toni K Choueiri, Laurence Albiges, Philippe Barthélémy, Roberto Iacovelli, Sheik Emambux, Javier Molina-Cerrillo, Benjamin Garmezy, Pedro Barata, Arnab Basu, Maria T Bourlon, Helen Moon, Raffaele Ratta, Rana R McKay, Alexander Chehrazi-Raffle, Hans Hammers, Daniel Y C Heng, Edgar Braendle, Kathryn E Beckermann, Bradley A McGregor, Robert J Motzer
{"title":"Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study.","authors":"Toni K Choueiri, Laurence Albiges, Philippe Barthélémy, Roberto Iacovelli, Sheik Emambux, Javier Molina-Cerrillo, Benjamin Garmezy, Pedro Barata, Arnab Basu, Maria T Bourlon, Helen Moon, Raffaele Ratta, Rana R McKay, Alexander Chehrazi-Raffle, Hans Hammers, Daniel Y C Heng, Edgar Braendle, Kathryn E Beckermann, Bradley A McGregor, Robert J Motzer","doi":"10.1016/S0140-6736(24)01758-6","DOIUrl":"10.1016/S0140-6736(24)01758-6","url":null,"abstract":"<p><strong>Background: </strong>Immune checkpoint inhibitors (ICIs) and vascular endothelial growth factor receptor tyrosine kinase inhibitors are cornerstones of first-line treatment for advanced renal cell carcinoma; however, optimal treatment sequencing after progression is unknown. This study aimed to assess clinical outcomes of tivozanib-nivolumab versus tivozanib monotherapy in patients with metastatic renal cell carcinoma who have progressed following one or two lines of therapy in the post-ICI setting.</p><p><strong>Methods: </strong>TiNivo-2 is a multicentre, randomised, open-label, phase 3 trial at 190 sites across 16 countries, in Australia, Europe, North America, and South America. Patients with advanced renal cell carcinoma and progression during or after one to two previous lines of therapy (including one ICI) were randomised 1:1 to tivozanib (0·89 mg per day, orally) plus nivolumab (480 mg every 4 weeks, intravenously) or tivozanib (1·34 mg per day, orally). Randomisation was stratified by immediate previous therapy (ICI or non-ICI) and International Metastatic Renal Cell Carcinoma Database Consortium risk category. The primary endpoint was progression-free survival (PFS), defined as the time from randomisation to first documentation of objective progressive disease according to RECIST 1·1 or death from any cause, whichever came first, by independent radiology review. Efficacy was evaluated in the intention-to-treat population, and safety was assessed in patients who received one or more doses of the study drug. This trial was registered on ClinicalTrials.gov (NCT04987203) and is active and not recruiting.</p><p><strong>Findings: </strong>From Nov 4, 2021, to June 16, 2023, 343 patients were randomly assigned to tivozanib-nivolumab (n=171) or tivozanib monotherapy (n=172). Median follow-up was 12·0 months. Median PFS was 5·7 months (95% CI 4·0-7·4) with tivozanib-nivolumab and 7·4 months (5·6-9·2) with tivozanib monotherapy (hazard ratio 1·10, 95% CI 0·84-1·43; p=0·49). Among those with an ICI as their immediate previous therapy (n=244), median PFS was 7·4 months (95% CI 5·6-9·6) with tivozanib-nivolumab and 9·2 months (7·4-10·0) with tivozanib monotherapy. With non-ICIs as the most recent therapy, lower median PFS was observed, with no difference between groups (tivozanib-nivolumab 3·7 months [95% CI 2·7-5·4] and with tivozanib monotherapy 3·7 months [1·9-7·2]). Serious adverse events occurred in 54 (32%) of 168 patients receiving tivozanib-nivolumab and 64 (37%) of 171 patients receiving tivozanib monotherapy. One (<1%) treatment-related death occurred (tivozanib group).</p><p><strong>Interpretation: </strong>These data further support that ICI rechallenge should be discouraged in patients with advanced renal cell carcinoma. Furthermore, these data suggest that tivozanib monotherapy has efficacy in the post-ICI setting.</p><p><strong>Funding: </strong>Aveo Pharmaceuticals.</p>","PeriodicalId":18014,"journal":{"name":"Lancet","volume":null,"pages":null},"PeriodicalIF":98.4,"publicationDate":"2024-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142290384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信